|Bid||645.63 x 800|
|Ask||662.89 x 800|
|Day's Range||647.54 - 664.85|
|52 Week Range||492.13 - 747.42|
|Beta (5Y Monthly)||0.21|
|PE Ratio (TTM)||10.57|
|Earnings Date||Feb 03, 2022 - Feb 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||702.05|
SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.
Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.